Predictors of treatment outcomes following anti-vascular endothelial growth factor (VEGF) therapy for Neovascular AMD.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/590205

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Age-related macular degeneration (AMD) is the most common cause of severe, irreversible loss of vision amongst elderly populations in the developed world. Bleeding in the retina destroys central vision. New treatments have been developed to stop this bleeding. However not all patients benefit equally, with some still losing vision. This project aims to investigate what determines how well an individual responds to treatment, in particular, how genes might influence the response.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $240,277.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Ophthalmology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

age related macular degeneration | ageing | complex genetic disease | eye diseases | genetic polymorphisms | improved prognosis | neovascularization | prediction | prognosis

Related Links